This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
F-18 fluoroestradiol (FES) PET may improve staging of grade 1 or 2 estrogen receptor (ER)-positive breast cancer compared with F-18 FDG-PET, according to an article published March 4 in Radiology. Nuclear medicine physicians analyzed both sets of images and determined disease stages, with final stages verified via biopsy. (B)
Alzheimer’s disease patients with cognitive impairment or dementia who were referred for amyloid PETscans had fewer hospitalizations compared with a matched control group, according to a study published October 9 in JAMA Neurology. Each participant was matched to a control Medicare beneficiary who had not undergone amyloid PET.
National Institutes of Health (NIH) has highlighted a study that shows cardiac PETscans can help identify people at risk for Parkinson’s disease and Lewy body dementia. Significantly, the research supports a “body first” progression model for the diseases, the researchers suggested. “We
PET imaging using a newly developed radiotracer has identified different patterns of brain tau pathology over time in early-onset versus late-onset Alzheimer’s disease patients, according to a study published February 1 in the Journal of Nuclear Medicine. in 15 patients with negative amyloid PETscans; 1.18 in
PET brain scans show persistent brain inflammation in patients with multiple sclerosis (MS), despite being treated with high-efficacy disease-modifying therapies, according to a recent study by researchers in Boston. The researchers performed F-18 PBR06 PETscans on 22 patients with MS and eight healthy controls.
A group in France has offered an explanation for long COVID brain fog, with the concept based on a visual brain pattern they discovered on patient PETscans, according to a study published October 13 in Medical Hypotheses. “We A) PETscan of a healthy subject. (B) B) PETscan of a long COVID patient.
PET imaging has revealed brain pathology linked to faster clinical progression of Alzheimer’s disease in patients with ApoE4 gene variants, according to a study published November 6 in JAMA Neurology. A link to the full article can be found here. The study authors included scientists at Eli Lilly and Company.
“To date, F-18 FDG PET findings are currently not taken into account when making a diagnosis for possible, probable, or definite neurosarcoidosis,” noted lead author Jessy Chen, MD, of Charité - Berlin University Medicine, and colleagues. The article was published January 25 in Neurological Research and Practice.
The group previously described developing the AI model in an article published last year. In this case, a 43-year-old man underwent an MRI scan that showed no contrast enhancement, yet hyperintensities were apparent in the patient’s left thalamus and frontoparietal region. Image courtesy of the Journal of Nuclear Medicine.
In addition to his other roles, Dr. Zelefsky will serve as a professor in the department and Genitourinary Cancer Disease Management Group leader. He comes to NYU Langone from Memorial Sloan-Kettering Cancer Center, where he held major leadership roles. “Dr.
In this article, we’ll delve into the hottest news and breakthroughs in imaging, highlighting the remarkable strides that have made the headlines. Check out our previous articles highlighting the impact that ChatGPT and Bard have made in 2023.
This standard has revolutionized the radiology industry, encompassing many imaging modalities such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, nuclear medicine, PETscans, etc. Combining multiple imaging techniques with DICOM even furthers accuracy in medical diagnosis!
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content